Delving into the Latest Updates on Bone marrow-derived mesenchymal stromal cells(The University of Queensland) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

bone marrow-derived mesenchymal stromal cells(The University of Queensland), Bone-marrow derived MSCs(The University of Queensland)

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Immune System Diseases

Active Indication

Allograft Rejection

Inactive Indication

Cardiomyopathy, DilatedCoronary Artery DiseaseIdiopathic cardiomyopathy+ [1]

Originator Organization

The University of Queensland

Active Organization

The University of Queensland

Inactive Organization

Hospital General Universitario Gregorio Marañón

Pharmicell Co., Ltd.

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

Start Date01 Sep 2025

Sponsor / Collaborator

Emory University

NCT03818737

/ CompletedPhase 3IIT

Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA)

The study is a multicenter trial conducted to compare the effectiveness of an injection of a corticosteroid control to mesenchymal stem cell (MSC) preparations from autologous bone marrow concentrate (BMAC), adipose derived stem cells in the form of Stromal Vascular Fraction (SVF), and third-party human mesenchymal stem cells manufactured from umbilical cord tissue (UCT) for the treatment of unilateral Knee Osteoarthritis (OA). The study will be conducted in 4 sites in the United States, and a total of 480 participants will be enrolled in this study.

Start Date28 Mar 2019

Sponsor / Collaborator

Emory University

[+1]

EUCTR2017-003524-75-NL

/ Unknown statusPhase 2IIT

Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells for the Treatment of Refractory Proctitis in Ulcerative Colitis - BMMSCproctitis

Start Date27 Mar 2018

Sponsor / Collaborator-

100 Clinical Results associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

100 Translational Medicine associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

100 Patents (Medical) associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

100 Deals associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Allograft Rejection	Phase 2	Australia	The University of Queensland	21 Apr 2017
Coronary Artery Disease	Phase 2	Spain	Hospital General Universitario Gregorio Marañón	31 Mar 2013
Idiopathic cardiomyopathy	Phase 2	Spain	Hospital General Universitario Gregorio Marañón	31 Mar 2013
Cardiomyopathy, Dilated	Phase 2	Spain	Hospital General Universitario Gregorio Marañón	01 Mar 2013
Liver Cirrhosis, Alcoholic	Phase 1	United States	Pharmicell Co., Ltd.	20 Jun 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03818737 (MILES, CTgov)	Phase 3	Osteoarthritis, Knee	475	Bone Marrow Derived MSCs (Bone Marrow Derived MSCs)	gmsxrgkxsc(xfnqfqfnng) = unzasibcsm vrliclhzuw (aczstbzjhe, 2.52) View more	-	27 Jul 2023
				Adipose-derived MSCs (Adipose-derived MSCs)	gmsxrgkxsc(xfnqfqfnng) = ufyaunihzl vrliclhzuw (aczstbzjhe, 2.48) View more
HOVON-113 (EHA2022) Manual	Phase 3	Steroid Refractory Graft Versus Host Disease	41	Mesenchymal stromal cell	tkstxziyym(uwtrgequpp) = neguuwbtjy rlrjzgezby (zhszmscgpp ) View more	Negative	12 May 2022
				placebo	tkstxziyym(uwtrgequpp) = qutazsbyvc rlrjzgezby (zhszmscgpp ) View more